Track topics on Twitter Track topics that are important to you
CARLSMED, Inc., a San Diego-based medical technology company, today announced the appointment of Sharon Schulzki as Chief Operating Officer (COO). Ms. Schulzki has deep experience building venture backed MedTech startups and has excelled in prior executive leadership roles with market leaders Stryker and Johnson & Johnson’s DePuy Synthes. She most recently led the exit of the 3D printing medical technologies company Tissue Regeneration Systems (TRS) to J&J DePuy Synthes and the licensing of TRS’s proprietary mineral coating technology to Medtronic Spine.
“We’ve made tremendous progress during the last year, and today I’m pleased to announce that Sharon has joined the team as COO,” said Mike Cordonnier, CEO and Co-Founder of CARLSMED. “Sharon’s track record of building value through execution of Evidence Development Plans and key surgeon engagement will ensure that CARLSMED’s platform achieves the mission of making personalized medical devices the preferred treatment option.”
Dr. Chris Ames, an advisor to CARLSMED, who is Director of Spinal Deformity and Spine Tumor Surgery at the UCSF Spine Center and has led the way in using advanced predictive modeling and AI to optimize the quality, value and safety of surgery for adult spinal deformity, stated, “CARLSMED is utilizing the vast diagnostic and outcomes data that we as surgeons collect about our patients to create the optimal devices for each new patient on demand. This should be the new standard of care for treatment of complex adult spine disorders and beyond – and Sharon is the right person to execute on the vision.”
CARLSMED is leveraging AI and predictive analytics to utilize prior outcomes data for personalizing the treatment of complex adult spinal deformities. The company’s proprietary PACC platform makes surgical plans and devices tailored to the precise medical situation of every individual patient. This is transforming healthcare by finally giving spine surgeons the tools to obtain better results at a lower cost of treatment while helping adults regain their active lifestyles.
CARLSMED is currently incubating at Southern California’s most successful technology startup incubator EvoNexus and maintains offices in San Diego and Seattle.
Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...